Lung cancer trials in Italy

In Italy 272 Also abroad 2733

272 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Where
Milan, Monza, Naples, Orbassano, Parma, Perugia, Pisa, Rome, Rozzano, Verona
Age
18 years and over
People
590 worldwide
Run by
Revolution Medicines, Inc.
See details and how to joinNCT06881784 · EU 2024-518154-16-00
No phaseTaking people
A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice
Where
Acquaviva Delle Fonti, Bergamo, Fano (PU), Genoa, Lecce, Mestre, Milan, Misterbianco (CT), Modena, Naples, Novara, Palermo, Ravenna, Rome, Sassari, Trento, Verona
Age
18 years and over
People
700 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07284121
Phase 2Taking people
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
Where
Aviano, Cagliari, Florence, Milan, Padova
Age
18 years and over
People
105 worldwide
Run by
Verastem, Inc.
See details and how to joinNCT07659782 · EU 2026-526472-23-00
Phase 1/2Taking people
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
Where
Meldola, Milan, Orbassano, Rome
Age
18 years and over
People
320 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT05789082 · EU 2023-507171-22-00
Phase 3Taking people
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Where
Aviano, Genoa, Livorno, Milan, Misterbianco (CT), Modena, Monza MI, Naples, Pesaro, Peschiera Del Garda (VR), Rome, Statte, Trento
Age
18 years and over
People
600 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06793215
Phase 3Taking people
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Where
Aviano, Bergamo, Caserta, Florence, Genoa, Milan, Napoli, Ravenna, Rome, Verona
Age
18 years and over
People
680 worldwide
Run by
Pfizer
See details and how to joinNCT07144280 · EU 2025-521281-97-00
Phase 3Taking people
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Where
Aviano, Milan, Naples, Orbassano, Parma, Ravenna, Rome
Age
18 years and over
People
850 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07361497 · EU 2025-523576-23-00
Phase 1/2Taking people
A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
Where
Milan, Orbassano, Padova, Parma, Ravenna, Rome
Age
18 years and over
People
160 worldwide
Run by
TRIANA Biomedicines, Inc.
See details and how to joinNCT07491497 · EU 2025-524418-27-00
No phaseTaking people
Immunonutrition for Improving the Efficacy of Immunotherapy in Patients With Metastatic Non-small Cell Lung Cancer
Where
Pavia
Age
18 years and over
People
180
Run by
Fondazione IRCCS Policlinico San Matteo di Pavia
See details and how to joinNCT05384873
Phase 3Taking people
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Where
Bari, Bologna, Catania, Milan, Naples, Padova, Rome, Varese, Verona
Age
18 years and over
People
1,264 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06119581 · EU 2023-503412-33-00
Phase 1Taking people
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Where
Milan
Age
18 years and over
People
575 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06400472 · EU 2024-511238-11-00
Phase 3Taking people
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Where
Avellino, Aviano, Bologna, Florence, Lecce, Meldola, Milan, Orbassano, Padova, Palermo, Rome, Rozzano, Verona
Age
18 years and over
People
444 worldwide
Run by
Bayer
See details and how to joinNCT06452277 · EU 2024-511319-91-00
Phase 3Taking people
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Where
Bari, Catania, Genova, Meldola, Milan, Monza, Naples, Orbassano, Rome, Verona
Age
18 years and over
People
700 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06890598 · EU 2024-512302-25-00
Phase 2Taking people
A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Where
Bergamo, Milan, Naples, Perugia, Siena
Age
18 years and over
People
254 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07492680
No phaseNot yet taking people in Italy
Gut Microbiome in Patients With Lung and Melanoma Cancer and Intestinal Microbiota in Gynecologic Cancers
Where
Milan
Age
18 years and over
People
360
Run by
European Institute of Oncology
See details and how to joinNCT07815873
Phase 3Taking people
A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation
Where
Aviano, Catania, Firenze, Medolo, Ravena, Reggio Emilia, Azienda Ospedaliero Universitaria di Bologna - Policlinico S. Orsola-Malpighi, Azienda USL Toscana Sud Est -Ospedale Misericordia - Grosseto, Azienda Ospedaliero-Universitaria di Modena (AOU Modena) - Policlinico di Modena, Azienda Ospedaliera San Gerardo - Monza, Azienda Ospedaliero - Universitaria di Parma, IRCCS Istituti Fisioterapici Ospitalieri- Istituto Nazionale tumori Regina Elena, Azienda Ospedaliera Universitaria Senese - (ITT) - Center for Immuno-Oncology (CIO), La Maddalena Casa di Cura di Alta Specialita - Palermo
Age
18 years and over
People
65 worldwide
Run by
Dizal Pharmaceutical Co. Ltd.
See details and how to join2022-502959-54-00 · EU 2022-502959-54-00
Phase 2Taking people
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Where
Genoa, Milan, Monza, Naples
Age
18 years and over
People
520 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05498428 · EU 2023-505065-91-00
Phase 3Taking people
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Where
Bari, Bergamo, Catanzaro, Florence, Meldola, Milan, Rome, Udine
Age
18 years and over
People
614 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06170788 · EU 2023-503376-24-00
Phase 2Taking people
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Where
Orbassano, Padova, Ravenna, Rome, Rozzano
Age
18 years and over
People
480 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06667076 · EU 2025-520730-28-00
No phaseTaking people
A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting
Where
Avellino, Aviano, Bari, Bergamo, Brescia, Candiolo, Catania, Catanzaro, Genova, Lecce, Milan, Monza, Naples, Novara, Olbia, Orbassano, Palermo, Parma, Pisa, Ravenna, Roma, Rome, Sassari, Torrette-Ancona, Urbino
Age
18 years and over
People
380 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07230691
Phase 2Taking people
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
Where
Candiolo, Meldola, Milan, Naples, Orbassano, Padova, Parma, Ravenna, Rome
Age
18 years and over
People
240 worldwide
Run by
Genmab
See details and how to joinNCT07288177 · EU 2025-522107-18-00
Phase 2/3Taking people
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
Where
Ancona, Aviano, Genoa, Milan, Naples, Peschiera del Garda, Rome, Siena
Age
18 years and over
People
750 worldwide
Run by
Eikon Therapeutics
See details and how to joinNCT07365319 · EU 2025-525013-23-00
Phase 2/3Taking people
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
Where
Avellino, Aviano, Bergamo, Bologna, Candiolo, Catania, Cremona, Ferrara, Lucca, Meldola, Milan, Misterbianco, Naples, Orbassano, Pavia, Peschiera del Garda, Rome, Siena, Udine
Age
18 years and over
People
1,580 worldwide
Run by
BioNTech SE
See details and how to joinNCT06712316 · EU 2024-515764-31-00
Phase 3Taking people
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy
Where
Alexandria, Brescia, Camaiore, Catania, Ferrara, Genoa, Lucca, Meldola, Milan, Pavia, Perugia, Peschiera del Garda, Ravenna, Reggio Emilia, Rome, Siena, Terni
Age
18 years to 90 years
People
507 worldwide
Run by
ImmunityBio, Inc.
See details and how to joinNCT06745908 · EU 2025-521221-32-00
Phase 3Taking people
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Where
Aviano, Milan
Age
18 years and over
People
480 worldwide
Run by
ArriVent BioPharma, Inc.
See details and how to joinNCT07185997